1. Introduction {#s0005}
===============

Pulmonary atresia (PA) is a rare complex congenital heart defect (CHD), which occurs in 0.01% of live births and 1.3--3.4% of all heart malformations [@b0005], [@b0010]. PA is a complex heart lesion with heterogeneity in embryogenesis, surgical strategy, prognosis, as well as anatomic variance. PA can be mainly classified into two categories according to whether there is a ventricular septal defect (VSD) or not: pulmonary atresia with ventricular septal defect (PA/VSD), pulmonary atresia with intact ventricular septum (PA/IVS) [@b0015], [@b0020], [@b0025].

PA/VSD belongs to conotruncal defect (CTD) which is characterized as a group of congenital cardiac outflow tract anomalies [@b0030]. PA/VSD shares many similar structural and pathological features with tetralogy of Fallot (TOF), and is considered as the most extreme form of TOF patients [@b0035], [@b0040]. PA/IVS is a rare heart lesion which is quite another matter [@b0045], [@b0050]. There are many differences in anatomical abnormalities between PA/VSD and PA/IVS. In PA/IVS, all components of the right ventricle (RV) can be affected since little blood flows into or out of RV, which leads to the undeveloped and hypoplastic inlet RV. Without early diagnosis and proper treatment, the survival rate of PA/IVS is extremely poor [@b0055].

With the improvements in surgical performance and cure rate, the focus of attention on pulmonary atresia has shifted from immediate outcomes to underlying mechanisms. A proportion of PA/VSD is reported to be associated with rare copy number variants, including deletions in 5q14.1dup (DHFR), 10p13dup (CUBN) and 17p13.2del (CAMTA2), and most of PA/VSD patients have 22q11 deletion syndrome [@b0060], [@b0065]. Other than chromosomal rearrangements, previous literatures have implicated rare damaging mutations in GAJ5, GDF1, MTHFR, MYH6, and HEY gene family that were detected in some PA/VSD patients [@b0070], [@b0075], [@b0080], [@b0085], [@b0090]. Previous studies have assumed that gene expression pattern in PA/VSD and PA/IVS should be different. But most of previous researches focused on PA/VSD, little is known about the prevalence and spectrum of genetic alterations in PA/IVS. He et al. conducted a genome-wide scanning in 54 PA/IVS patients and 20 PA/VSD patients and found that no rare CNVs were detected in patients with PA/IVS, which might be totally different from PA/VSD in terms of genetics as well as anatomy [@b0095]. The exact differences of genetic pattern between PA/VSD and PA/IVS remain unknown, which requires further study to emphasize the marked heterogeneity and etiological complexity of these rare and complex CHDs.

Genetic factors play an important role in PA although no major pathogenic gene has been identified to date. Previously reported pathogenic genes cover only a small part of the molecular mechanism underlying PA pathogenesis, it still lacks enough evidence to evaluate the contribution of gene pattern in different subtypes of PA [@b0100], [@b0105], [@b0110]. Therefore, we applied whole exome sequencing technology to identify the genes pattern in 100 PA cases and 100 healthy controls. Then we detected the expression pattern of candidate genes in HPAECs, human pulmonary artery, and human embryonic hearts. At last, we considered 7 genes (*DNAH10, DST, FAT1, HMCN1, HNRNPC, TEP1,* and *TYK2*) as the novel candidate genes that most likely underlie PA pathogenesis. Our findings demonstrate that rare damaging variants could lead to the occurrence of PA. Moreover, we identified novel candidate genes which have never been reported as related to the development of pulmonary artery. Our study is also an effort to distinguish the genetic pattern between PA/VSD, PA/IVS and TOF/PA. These results could fill the void of the underlying mechanism of PA, and assist in the identification of candidate genes for PA/VSD, PA/IVS and TOF/PA.

2. Materials and methods {#s0010}
========================

2.1. Study population {#s0015}
---------------------

Our cohort included sporadic cases with PA/VSD (n = 60), TOF/PA (n = 20), PA/IVS (n = 20) and 100 healthy controls diagnosed by echocardiogram, cardiac catheterization, or surgery. Patients with an identified chromosomal or syndromic disorder or a situs anomaly were excluded. The present study was approved by the Ethics Committee of the Xinhua Hospital Affiliated to the Shanghai Jiao Tong University School of Medicine and was conducted according to the principles expressed in the Declaration of Helsinki. Participants and/or their legal guardians involved in this study gave a written informed consent prior to inclusion in the study.

2.2. DNA extraction and whole exome sequencing (WES) {#s0020}
----------------------------------------------------

Genomic DNA samples of the PA cases and healthy controls were obtained with written informed consent. DNA extraction from blood samples was carried out using the QIAamp™ DNA and Blood Mini kit (Qiagen) according to the manufacturer\'s instructions. WES was performed using the Agilent Sure Select Target Enrichment kit (V6 58 Mb; Agilent Technologies) for sequence capture and the Illumina HiSeq2500 for sequencing (Illumina) to a target depth of 100×.

2.3. Reads mapping, variants calling and annotation {#s0025}
---------------------------------------------------

The whole exome sequencing reads of 300 bp (150 bp at each end) were mapped to UCSC human reference genome (GRCh37/hg19 assembly) using BWA-mem mode [@b0115] with default options followed by removal of PCR duplicates, low-quality reads (BaseQ \< 20). The resulting SAM files were then sorted and indexed by samtools [@b0120]. The variant calling was performed by the Genome Analysis Toolkit (GATK) best-practices workflow [@b0125]. The variants were annotated by ANNOVAR (20601685) with the databases of RefSeq gene, SIFT [@b0130], PolyPhen [@b0135], MutationTaster [@b0140], 1000G [@b0145], and ExAC and gnomAD [@b0150]. As illustrated in [Fig. 1](#f0005){ref-type="fig"}, the rare damaging variants were finally screened using the American College of Medical Genetics (ACMG) criteria guidelines [@b0155].Fig. 1The schematic diagram of systematic data analysis of the PA-associated genes/variants. An analytical strategy workflow of the different steps taken during whole-exome sequencing analysis with gene expression detection is shown. After variant calling and annotation, variants were then filtered by variant-based association analysis, gene-based burden analysis. Candidate genes were collected by gene expression analysis and network analysis. WES, whole-exome sequencing; PA/VSD, pulmonary atresia with ventricular septal defect; PA/IVS, pulmonary atresia with intact ventricular septum; TOF, tetralogy of Fallot; SNP, single nucleotide polymorphism; MAF, minor allele frequency; FDR, false discovery rate.

2.4. PA-associated genes and variants {#s0030}
-------------------------------------

The Fisher's exact test was conducted to test the association between variants and the disease status. The SNP status was encoded as 0 or 1, where 0 indicated that no SNP alleles were found, and 1 indicated that at least 1 SNP allele was detected. The SNP status and sample class labels where 1 indicated PA patients and 0 indicated control samples were used to obtain the 2 × 2 contingency table for Fisher\'s exact test, and *P*-value \< 1e−4 was considered statistically significant. Furthermore, we aggregated the SNP data at the gene level. The samples were considered as mutated samples at gene level if they carried at least one rare mutation of the given gene. Similarly, the gene-burden-based association was determined by Fisher's exact test. The gene level *P-*values were adjusted with the false discovery rates (FDR) method, where FDR \< 0.05 or *P*-value \< 0.005 was considered statistically significant.

2.5. Protein--protein interaction (PPI) analysis {#s0035}
------------------------------------------------

The protein--protein interactions were extracted from the Search Tool for the Retrieval of Interacting Genes (STRING) database (<http://string-db.org>) [@b0160], [@b0165], which could critically assess and integrate protein--protein interactions (PPI), including both direct (physical) and indirect (functional) associations. The gene set consisting of known PA genes and the 20 statistically significant PA-associated genes were mapped to the PPI network together. With the removal of the proteins without connected nodes, the resulting PPI subnetwork constructed by the known and novel PA genes were visualized by Cytoscape [@b0170].

2.6. Gene expression analysis of the microarray datasets {#s0040}
--------------------------------------------------------

The gene expression datasets (GSE67492 [@b0175] and GSE30428 [@b0180]) of cardiomyocytes were collected from Gene Expression Omnibus (GEO) database, which normalized the gene expression data. In addition, our previously published time course expression data of human embryonic heart were measured using Affymetrix HTA 2.0 microarray platform [@b0185]. The median of expression levels across the samples was used to represent the expression level for each gene. The rankings of the PA-associated genes in the expression profiles were visualized by R/Bioconductor fgsea package.

2.7. RNA extraction and RT-qPCR assay {#s0045}
-------------------------------------

Total RNA was extracted from Human Pulmonary Artery Endothelial Cells (HPAECs), pulmonary artery and embryonic heart from humans, respectively. HPAECs were obtained from the Chinese Academy of Sciences (Shanghai, China). The human tissue samples consisted of pulmonary artery from 3 healthy controls and Carnegie stages 11 through 15 human embryonic heart harvested from Shanghai Xinhua Hospital. The integrity and purity of the RNA was detected by the Experion automated gel electrophoresis system (Bio-Rad) and the NanoDrop 2000c spectrophotometer (ThermoFisher Scientific) [@b0190]. RNA extraction and the RT-qPCR procedure were described previously. The RT-qPCR primers are listed in [Supplementary Table S1](#s0130){ref-type="sec"}.

2.8. PA-subtype associated genes {#s0050}
--------------------------------

The genes that were only present in one of PA/VSD, TOF/PA, or PA/IVS and absent in controls were considered as potential PA-subtype associated genes. For each gene, the samples with variants should be more than 2. To detect potential relationships among these subtype candidate genes, we mapped all these subtype genes and known PA genes to the STRING network and visualized the network using Cytoscape. Moreover, we compared the number of total variants, nonsynonymous SNVs, and LOF variants among these three subtypes.

3. Results {#s0055}
==========

3.1. Overview of pathogenic gene discovery based on WES data analysis {#s0060}
---------------------------------------------------------------------

The present cohort of 100 unrelated patients with PA were collected from Shanghai Xinhua Hospital, which consisted of 60 PA/VSD patients, 20 PA/IVS patients, and 20 TOF/PA patients ([Table 1](#t0005){ref-type="table"}). In addition, 100 healthy people were collected as normal controls. The whole exome sequencing was conducted on all 200 samples. As illustrated in [Fig. 1](#f0005){ref-type="fig"}, the analysis of whole exome sequencing (WES) data from the 100 PA cases and 100 healthy controls successfully called 835,179 variants with high confidence. Following ACMG criteria guidelines, we screened a total of 11,946 rare damaging variants with a threshold of minor allele frequency (MAF) at 0.5% in databases of gnomAD, 1000G, and ExAC [@b0150], and the deleteriousness was predicted by bioinformatics tools (see Materials and methods). The downstream analyses including variant-based association analysis, gene-based burden analysis, known PA genes/variants, and comparative analysis of PA subtypes, were conducted based those variants.Table 1Summary of demographic and clinical information of 100 study patients.Patient characteristicsPA/VSDPA/IVSTOFMean age at diagnosis (years)4.4 ± 3.550.84 ± 0.431.66 ± 2.6Female, n, (%)21(35)10(50)8(40)Male, *n*, (%)39(65)10(50)12(60)Total, n602020Female-to-male ratio1:1.91:11:1.5Associated cardiac lesion, n, (%)Left superior vena cava (LSVC)1(5)02(10)Right aortic arch (RAA)1(1.7)2(10)3(15)Total anomalous pulmonary vein connection (TAPVC)01(5)0Aortic stenosis (AS)01(5)1(5)

3.2. The overall comparison of the rare damaging variants between the PA and control groups {#s0065}
-------------------------------------------------------------------------------------------

Based on the 11,946 rare damaging variants, we found more variants in PA group than that in control (Wilcoxon rank-sum test, *P* \< 2.2e−16), consistently, which was also observed in missense variant, nonsense variant, frameshift insertion or deletion, and splice variant ([Fig. 2](#f0010){ref-type="fig"}A). Moreover, the SNP accounted for most the variant types in both case and control groups ([Fig. 2](#f0010){ref-type="fig"}B). C \< T mutation occupied the most of base mutation than other types ([Fig. 2](#f0010){ref-type="fig"}C). The ratios between transitions and transversions in PA and control groups were about 2.00 and 1.98, which was close to 2 of theoretical ratio.Fig. 2The comparisons of the rare damaging variants between the PA and control groups. The number of variants in each variant classification, variant type, and SNV class are presented in (A), (B), and (C), respectively. (D) PA-associated variants by Fisher's exact test. Each node represents a variant, and the y-axis represent the statistical significance level. The threshold of the *P*-value is 0.0001, which is represented by the red line. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

3.3. Identification of PA-associated variants by Fisher\'s exact test {#s0070}
---------------------------------------------------------------------

To identify the PA-associated variants, we conducted Fisher's exact test on the rare damaging variants as described above. We observed six variants that were more frequently detected in PA group than in control group (FDR \< 0.05, [Fig. 2](#f0010){ref-type="fig"}D). The six variants were located within *SLC9B1*, *MUC6*, *HNRNPC*, *OR11H12*, and *ATXN3*. Particularly, two variants fell from the same gene of *HNRNPC*, which showed a predominant significance (*P*-value \< 1e−15). Moreover, the variant in *SLC9B1* also exhibited a significance level similar to the variants in *HNRNPC*, suggesting that these two genes may play key roles in PA pathogenesis.

3.4. Identification of PA-associated genes by gene-based burden test {#s0075}
--------------------------------------------------------------------

To identify PA-associated genes, we first aggregated the variants at the gene level, and then performed the Fisher's exact test for each gene. Given loose thresholds of 0.05 for *P*-value and 3 PA cases with more than one variant, we identified 178 genes with potential pathogenicity ([Fig. 3](#f0015){ref-type="fig"}A), of which, *ATXN3*, *TTN*, *HNRNPC*, *SLC9B1*, *OBSCN*, *MUC4*, *FAT1*, *OR11H12*, and *DST* were considered as the ones with high confidence ([Fig. 3](#f0015){ref-type="fig"}B, FDR \<0.05). In accordance with the PA-associated variants, *HNRNPC*, *SLC9B1*, *OR11H12*, and *ATXN3* were also identified by the gene-based burden test. In addition, we also identified another eleven genes with relatively low confidence (*P*-value \<0.005). Totally, 20 genes were identified as PA-associated.Fig. 3The PA-associated genes identified by gene-based burden analysis. (A) The word-cloud of the PA-associated genes (*P* \< 0.05 & mutated in more than 3 samples). (B) The landscape of the PA-associated genes in cases and controls. The bars on the top and right of the panel represent the number of variant types for each sample and each gene, respectively. The grey cells indicate that no variants were detected in the corresponding samples. (C) The corrplot of 20 genes were identified by gene-based burden analysis, where \**P* \< 0.05 and \**P* \< 0.1. (D) The protein--protein interaction (PPI) network of known (green nodes) and novel (blue nodes) PA-associated genes. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

As complex genetic disorders may have multiple pathogenic genes, these genes were generally co-occurred in the same sample, or exclusively occurred in different samples. Specifically, *HNRNPC* was exclusive of *OR11H12* and *SLC9B1* ([Fig. 3](#f0015){ref-type="fig"}C, *P* \< 0.1), respectively. In contrast, other 8 gene pairs, such as *SDK1*-*MUC4*, *DNAH1*-*DNAH10*, *DNAH1*-*FAT1*, and *SDK1*-*PCDHGA8*, were observed to be co-occurred in PA samples (*P* \< 0.1). These results suggested that gene pairs with exclusivity or co-occurrence might be involved in the same biological process or cooperated with each other to cause the disease.

To further investigate the roles of the PA-associated genes by gene-based burden test, we mapped the PA-associated genes and 45 manually curated known PA genes to the PPI network ([Supplementary Table S2](#s0130){ref-type="sec"}). We observed that *HNRNPC*, *TEP1*, *TTN*, *NEB*, *OBSCN*, *SYNE2*, and *PKD1* were directly or indirectly connected with the subnetwork of the known PA genes ([Fig. 3](#f0015){ref-type="fig"}D). In addition, two gene pairs, *DNAH1*-*DNAH10* and *FRAS1*-*HMCN1*, related to each other in the PPI network. Particularly, *DNAH1*-*DNAH10* was also observed to be co-occurred in PA samples, which suggested that interaction between *DNAH1* and *DNAH10* may play key roles in the occurrence of PA.

3.5. Comprehensive analysis of the expression levels of the PA-associated genes {#s0080}
-------------------------------------------------------------------------------

To further investigate the potential function of the PA-associated genes/variants in heart or cardiomyocyte, we collected two publicly available gene expression datasets (GSE67492 and GSE30428) of heart right ventricular from Gene Expression Omnibus (GEO). We observed that 20 PA-associated genes were significantly enriched in the genes with high expression in these two datasets (*P* \< 0.05, [Fig. 4](#f0020){ref-type="fig"}A and 4B) based on the gene set enrichment analysis (GSEA). *TTN*, *DST*, *HNRNPC*, *SYNE2*, and *OBSCN* were highly expressed at top 15% in human heart tissues of both datasets. Moreover, we also investigated the expression levels of these genes in human embryonic hearts, which was published by our previous study [@b0185], and found that *TTN*, *HNRNPC*, *FAT1*, *FRAS1*, and *DST* expressed higher than 75% quantile of the total genes ([Fig. 4](#f0020){ref-type="fig"}C). The integrative analysis of the gene expression and PPI network revealed that *TTN*, *HNRNPC*, *SYNE2*, and *OBSCN* may be the critical genes for PA occurrence. Notably, *HNRNPC* was the most significant PA-associated gene/variant.Fig. 4The expression levels of the PA-associated genes in heart. The expression levels of novel PA-associated genes were investigated in cardiomyocytes of GSE67492 (A), GSE30428 (B), and human embryonic hearts (C). RT-qPCR was conducted to detect the expression levels of these novel PA-associated genes in HPAECs (D) and human pulmonary artery (E).

To further filter the novel candidate genes of PA, we used RT-qPCR assay to detect the mRNA levels of the 21 candidate genes and 5 known PA genes in HPAECs, human pulmonary artery tissues harvested from 3 controls. Then, we further filtered these genes according to whether they were highly expressed in different tissues. By assessing gene expression in different samples, we finally obtained 7 candidate genes and 56 rare damage-associated nonsynonymous variants in our WES data ([Table 2](#t0010){ref-type="table"}). Finally, we got 7 candidate genes (*DNAH10, DST, FAT1, HMCN1, HNRNPC, TEP1,* and *TYK2*) and 4 known PA genes (*DOCK6, FANCD2, FGD5,* and *NOTCH1*) both expressed in cell line and human tissue ([Fig. 4](#f0020){ref-type="fig"}D).Table 2Rare variant of 7 candidate genes associated with PA.ChromosomePositionBase changeGeneAAChangeTxChangeExAC1000GgnomADSIFTPolyphen2Mutation\
TasterChr12124270362A \> GDNAH10p.M373Vc.A1117G------DDDChr12124311277A \> GDNAH10p.N1290Sc.A3869G6.63E −05----DPDChr12124317860A \> GDNAH10p.E1464Gc.A4391G------DDDChr12124333343C \> TDNAH10p.R1888Xc.C5662T2.88E−05--3.23E−05----AChr12124341713C \> -DNAH10p.C2065fsc.6195delC9.47E−06----------Chr12124349245C \> TDNAH10p.R2220Wc.C6658T1.91E−05--6.46E−05DDDChr12124399076C \> TDNAH10p.T3400Mc.C10199T0.00040.010.0005DDDChr12124409730T \> CDNAH10p.V3849Ac.T11546C------DDDChr12124409745G \> ADNAH10p.G3854Ec.G11561A0.00050.010.0006DDDChr656357793T \> CDSTp.N4711Sc.A14132G1.07E−05--3.23E−05TD--Chr656362244T \> CDSTp.H4600Rc.A13799G2.85E−05----TD--Chr656376149T \> CDSTp.N4090Sc.A12269G------TD--Chr656391232C \> TDSTp.R3900Hc.G11699A1.90E−05--3.23E−05DD--Chr656417016G \> ADSTp.T3406Mc.C10217T2.87E−05--3.23E−05TD--Chr656434698A \> GDSTp.S2493Pc.T7477C------TD--Chr656475225C \> ADSTp.K1728Nc.G5184T------DD--Chr656494178T \> CDSTp.K1416Ec.A4246G------DD--Chr656494186T \> ADSTp.E1413Vc.A4238T------DD--Chr656499727A \> GDSTp.Y1038Hc.T3112C------DD--Chr656504561G \> ADSTp.T844Ic.C2531T0.0004--0.0004TD--Chr656504843G \> ADSTp.R802Cc.C2404T4.74E−05--6.46E−05DD--Chr656569155C \> TDSTp.V234Mc.G700A----3.23E−05DD--Chr656819282A \> CDSTp.F35Cc.T104G6.76E−05--6.46E−05DD--Chr4187517784C \> TFAT1p.V4304Mc.G12910A9.72E−06----DDDChr4187525089T \> AFAT1p.I3531Fc.A10591T------DPDChr4187527348G \> AFAT1p.T3409Mc.C10226T0.00010.00173.24E−05TDDChr4187535411T \> CFAT1p.N3055Dc.A9163G0.0001--9.68E−05DDDChr4187539275A \> GFAT1p.L2822Pc.T8465C0.00070.010.0003DPDChr4187539671T \> CFAT1p.Y2690Cc.A8069G4.74E−05--6.46E−05TDDChr4187540271G \> AFAT1p.P2490Lc.C7469T------DDDChr4187542491G \> CFAT1p.T1750Rc.C5249G------DDDChr4187549895G \> TFAT1p.T1449Kc.C4346A------DDDChr4187584696C \> TFAT1p.D1113Nc.G3337A0.00020.010.0002DDDChr1186008985G \> CHMCN1p.V2052Lc.G6154C------TDDChr1186038870C \> THMCN1p.A2652Vc.C7955T0.0001--6.46E−05TDDChr1186056393G \> AHMCN1p.G3031Sc.G9091A4.72E−050.00179.71E−05DDDChr1186060046T \> GHMCN1p.I3295Sc.T9884G9.51E−06--9.72E−05DPDChr1186064443A \> GHMCN1p.M3455Vc.A10363G1.89E−05--3.23E−05DPDChr1186106797C \> THMCN1p.P4584Sc.C13750T2.83E−05--3.23E−05DDDChr1186147652G \> THMCN1p.D5350Yc.G16048T------DDDChr1186157125C \> THMCN1p.R5509Wc.C16525T6.60E−05----DDDChr1421679599T \> CHNRNPCp.D268Gc.A803G0.0025--0.0022TDDChr1421679600C \> AHNRNPCp.D268Yc.G802T0.0025--0.0022TDDChr1420836703A \> GTEP1p.C2593Rc.T7777C------DDDChr1420846278G \> ATEP1p.R1876Wc.C5626T4.71E−05--9.70E−05DDNChr1420850789T \> CTEP1p.Y1378Cc.A4133G0.00020.00179.71E−05DDNChr1420852074A \> TTEP1p.S1180Tc.T3538A2.24E−05----TDDChr1420854615C \> TTEP1p.R951Hc.G2852A2.94E−05--3.23E−05TDNChr1420854642C \> TTEP1p.R942Hc.G2825A9.59E−06--3.23E−05DDDChr1910468778G \> ATYK2p.R738Wc.C2212T7.42E−05----DDDChr1910469928G \> ATYK2p.R700Wc.C2098T3.98E−05--3.23E−05DDDChr1910472598C \> TTYK2p.V603Mc.G1807A0.0003--0.0002DDNChr1910473102G \> ATYK2p.R503Xc.C1507T1.22E−05--------AChr1910476375C \> TTYK2p.V277Mc.G829A5.98E−05--3.23E−05DDNChr1910477205C \> TTYK2p.E173Kc.G517A5.65E−05----DDDChr1910489024T \> GTYK2p.Q20Pc.A59C5.70E−05--3.24E−05TPD

3.6. Mutational spectrum of known PA-associated genes in our cohort {#s0085}
-------------------------------------------------------------------

In addition to the novel PA-associated genes/variants, the presence and mutational spectrum of known PA-associated genes in our cohort was also investigated. With a threshold of *P*-value at 0.05, *NOTCH1*, *DOCK6*, *FANCD2*, *FGD5*, and *FLT4* were identified as significant known PA-associated genes ([Fig. 5](#f0025){ref-type="fig"}A). The mutational spectrum of these genes showed that the missense variants were mostly located within the functional domains of the corresponding proteins ([Fig. 5](#f0025){ref-type="fig"}B). Particularly, all the four missense variants of *FANCD2* were located within the *FANCD2* domain, suggesting that *FANCD2* domain was an important functional domain for this protein, and may be closely associated with PA ([Fig. 5](#f0025){ref-type="fig"}B). Moreover, we also observed a hotspot of *FGD5* at the splice site of the 2527th nucleotide of the coding sequence ([Fig. 5](#f0025){ref-type="fig"}B). In addition, the four missense variants in *FLT4* were located within the functional domains, while the nonsense variant at the 82nd amino acid disrupted all the functional domains. The mutational spectrum of the known PA genes improved our understanding of the functional roles of these variants in PA.Fig. 5Mutational spectrum of five known PA genes. (A) The distribution of the five known PA genes, *NOTCH1, DOCK6, FANCD2, FGD5,* and *FLT4*, in the PA cases. (B) The specific amino acid sites of variants on the encoded proteins or protein domains.

3.7. Comparative analysis of the PA subtypes {#s0090}
--------------------------------------------

As we described above, the exact differences of genetic pattern between PA/VSD, TOF/PA, and PA/IVS remains unknown. We next performed comparative analysis and identified 11, 16, and 13 genes that only presented in PA/VSD, TOF/PA, and PA/IVS, respectively (n ≥ 2, [Fig. 6](#f0030){ref-type="fig"}A). Most of these genes were directly connected with the known PA genes ([Fig. 6](#f0030){ref-type="fig"}B). Moreover, the total number of rare damaging variants was observed to be higher in TOF/PA than in PA/VSD and PA/IVS ([Fig. 6](#f0030){ref-type="fig"}C, *P* \< 0.1). More specifically, TOF/PA has more nonsynonymous SNVs than PA/IVS and PA/VSD, while PA/VSD has more loss-of-function (LOF) variants than PA/IVS and TOF/PA ([Fig. 6](#f0030){ref-type="fig"}C, *P* \< 0.1).Fig. 6PA-subtype associated genes/variants and variant types. (A) The PA-subtype-specific genes that only present in one of the three subtypes, and absent in controls. (B) The PPI subnetwork constructed by mapping the known PA genes and the PA-subtype associated genes. (C) The comparisons between the three PA-subtypes about the number of total variants, nonsynonymous SNVs, and LOF variants.

4. Discussion {#s0095}
=============

As a class of rare congenital heart disorders, the genetic etiology and underlying mechanism of PA remains unclear. To clarify the underlying genomic risks of PA and the differences in genetic background among PA/VSD, TOF/PA, and PA/IVS, we adopted WES to identify rare damaging variants and novel candidate genes in 100 PA cases and 100 healthy controls. Further network analysis and gene expression analysis demonstrated *DNAH10, DST, FAT1, HMCN1, HNRNPC, TEP1,* and *TYK2,* as the totally novel genes associated with PA pathogenesis. Since the genetic pattern between PA/VSD, PA/IVS and TOF/PA remain elusive, we had already tried to find out the differences in gene mutations and gene levels among these three types. However, since the number of patients differed widely (PA/VSD, n = 60; TOF/PA, n = 20; PA/IVS, n = 20), our candidate genes from variant-based association analysis and gene burden analysis in case-control were not figured out in any subtypes. We adopted comparative analysis and identified 11, 16, and 13 specific genes that only presented in PA/VSD, PA/IVS, or TOF/PA. In PPI network, we found that most of these genes were directly connected with the known PA genes. We hope to perform further study with larger sample size soon.

*HNRNPC* belongs to the subfamily of heterogeneous nuclear ribonucleoproteins (hnRNPs). Two rare variants were detected in 31 PA/VSD patients, 13 TOF/PA patients, 9 PA/IVS patients with a high percentage of 53% in our cohort. Moreover, we observed that *HNRNPC* was directly connected with the subnetwork of the known PA genes. Further investigation found that *HNRNPC* had high expressions in HPAECs, human pulmonary artery tissues, and human embryonic hearts, the same as observed in two publicly available gene expression datasets. Heterogeneous Telomere bound hnRNPs including hnRNP A1, A2-B1, D and E, and telomerase bound hnRNPs including hnRNPA1 C1/C2 and D [@b0195]. *HNRNPA1* was highly expressed during cardiac development and two rare mutations of *HNRNPA1* were detected in human CHDs. *HNRNPA1*^-/-^ mice displayed the VSD, PTA, DORV phenotypes, and such modification led to the dysregulation of cardiac transcription factors, including Isl1, Nkx2.5, and Tbx1, and of signaling pathways, including BMP, FGF, and Notch pathways [@b0200], [@b0205]. Since then, *HNRNPC* was considered as the most significant and novel candidate genes for patients of PA. *TEP1*, which is a component of the ribonucleoprotein complex responsible for telomerase activity which catalyzes the addition of new telomeres on the chromosome ends, was observed to have strong correlation with *HNRNPC,* which directly connected with known PA genes in PPI network. *TEP1* was detected to have 6 rare damaging variants from 6 PA/VSD, 1 PA/IVS and 1 TOF/PA patients. Although the expression of *TEP1* was relatively low, we still conjectured that TEP1 and *HNRNPC* might have common effects on PA pathogenesis. Since the relationship between *HNRNPC, TEP1* and congenital heart defect remained unclear, their functions deserved to be further studied.

*DNAH1* and *DNAH10* belong to a component of the inner dynein arms, which could be found in cilia and flagella and consist of the outer and inner dynein arms attached to the peripheral microtubule doublets. Our previous study showed that *DANH10* played an important role in the pathogenesis of defects in heterotaxy syndrome patients with congenital heart defects [@b0210]. In our cohort, 5 PA/VSD patients and 5 TOF/PA patients were detected to have the rare variants in *DANH1,* while 9 PA/VSD, 1 TOF/PA and 3PA/IVS were detected in *DANH10*. We found that *DNAH1*-*DNAH10* was observed to be co-occurred in corrplot and they had a directly connection in network. We concluded that the gene pairs with co-occurrence might be relevant to the same biological process associated with PA pathogenesis. *FAT1* encodes a tumor suppressor essential for cellular polarization, directed cell migration and modulating cell--cell contact [@b0215]. *FAT1* had 10 rare damaging variants appearing in 7 PA/VSD, 3PA/IVS, and 7 TOF/PA after filtering the WES data, which was co-occurrence with *DNAH1*. We found that *FAT1* was highly expressed during human heart embryogenesis, yet whether *FAT1* play a causal or modifier role in PA is still elusive. Lacking literature supports, the underlying mechanism of this interaction of *DNAH1*- *DNAH10* and *DNAH1*-*FAT* need further study.

*DST* belongs to a member of the plakin protein family of adhesion junction plaque proteins, which has multiple cytoskeleton-binding domains. It exhibited a high expression in heart and pulmonary artery tissues in GSEA analysis [@b0220], [@b0225]. 13 rare damaging variants of *DST* were discovered in 9 PA/VSD, 2TOF/PA, 3PA/IVS patients. In accordance to previous studies, *DST* plays an important role in cell--cell adhesion structures, including desmosomes, gap junctions, and adherens junctions of cardiac muscle [@b0230]. 3 PA/VSD, 3 TOF/PA, and 2 PA/VSD patients had 8 rare damaging variants in *HMCN1,* which encodes a large extracellular member of the immunoglobulin superfamily. *HMCN1* showed the similar significance mRNA expression level as *HNRNPC.* Previous study demonstrated that *HMCN1* could affect the formation of transient cell contacts that are required for tissue organization, migration, invasion, as well as the formation of stable cell--cell and cell--ECM contacts by TGF-β signaling pathway [@b0235]. *TYK2* encodes a member of the tyrosine kinase, which associates with the cytoplasmic domain of type I and type II cytokine receptors and promulgates cytokine signals by phosphorylating receptor subunits [@b0240], [@b0245]. *TYK2* got 7 rare damaging variants in 7 PA/VSD, 2 PA/IVS patients. Thus far, the functions of *DST, HMCN1* and *TYK2* in cardiovascular development remain unknown, and they might be associated with PA pathogenesis in novel manners.

Our study did have some limitations. First, small sample size made it difficult to conform our candidate genes in validation cohort. Then the lack of parental samples limited our ability to study the genetic backgrounds of these patients. In addition, the functions of our candidate genes need to be further verified with transgenic animal research. In summary, an effective analytical bioinformatic approach allowed us to identify rare damage variants in novel genes, which would play a vital role in PA pathology. Our candidate genes open new fields of investigation into PA pathology and provide novel insights into pulmonary artery development.

5. Conclusions {#s0100}
==============

This analysis supports 7 novel candidate genes (*DNAH10, DST, FAT1, HMCN1, HNRNPC, TEP1,* and *TYK2*) which have not previously been reported in either humans or animals, contributing to the etiology of PA. Different subtypes of PA, namely PA/VSD, PA/IVS and TOF/PA had different genetic pattern to a certain extent. Overall, the data presented here builds confidence in further exploring the underlying mechanism of PA, which will encourage further verification with fundamental research.
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